O.04 Results from the IASLC Global Survey on Molecular Testing in Lung Cancer
Marileila Garcia(University of Colorado Anschutz Medical Campus), Fred R. Hirsch(Tisch Hospital), Pieter E. Postmus(Leiden University Medical Center), C. Mathias(Real Hospital Português), Liliana Dalurzo(Hospital Italiano de Buenos Aires), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), E. Kim(Levine Cancer Institute), Ross A. Soo(National University Cancer Institute, Singapore), Masahiro Tsuboi(National Cancer Center Hospital East), Kristen E. Howell(Texas A&M University), Sylvie Lantuéjoul(Centre Léon Bérard), Murry W. Wynes(International Association for the Study of Lung Cancer), K. Richeimer(International Association for the Study of Lung Cancer), Giorgio V. Scagliotti(Ospedale San Luigi Gonzaga), Suresh S. Ramalingam(Emory University), Enriqueta Felip(Institut Català d'Ornitologia), Charles S. Powell(National Jewish Health), Keith M. Kerr(University of Aberdeen), K. Wood(International Association for the Study of Lung Cancer), Matthew Smeltzer(University of Memphis), Meghan M. Taylor(University of Memphis)
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k